Study Raises Flag on PSA Test
The findings of a new study on prostate screening have sparked a debate among physicians on how to interpret the prostate-specific antigen (PSA) test and how to treat men who are not symptomatic.Whereas several factors play a role in a man's risk of developing prostate cancer, many physicians agree that a score above 4 on the PSA test may indicate cancer.
Yet, the current study reported in the New England Journal of Medicine (May 27, 2004) dispels the theory. The study, which involved 2940 men aged 62 to 91, found cancers in 15% of those with PSA levels below 4. The risk of prostate cancer rose with increasing PSA levels. Some experts believe that the findings illustrate the need for more aggressive cancer screening and treatment. In early 2004, the National Comprehensive Cancer Network recommended that physicians consider biopsies for men with PSA levels above 2.5.
The researchers in the new study, however, said that such thresholds may no longer be very useful. "There is no magic cutoff below which a man can assume he is completely free of risk or above which he must feel compelled to have a biopsy," said study author Howard Parnes, MD. "We need to allow each man, with the help of his physician, to assess his own risk."
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025